Enhancement of brain distribution of anticancer agents using ΔG, the 12 kDa active fragment of ZOT

International Journal of Pharmaceutics

Volumn 306, Issue 1-2, 2005, Pages 122-131

  Menon, Divya ^a   Karyekar, Chetan S ^c   Fasano, Alessio ^b   Lu, Ruliang ^b   Eddington, Natalie D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

G; Blood brain barrier; Brain distribution; Permeation enhancer; Tight junctions; ZOT

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; CARBON 14; CARBON DIOXIDE; CELL PROTEIN; DELTA G PROTEIN; MARKER; METHOTREXATE; PACLITAXEL; PROTEINASE INHIBITOR; SUCROSE; TRITIUM; UNCLASSIFIED DRUG; ZONNULA OCCLUDENS TOXIN;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASPHYXIA; BLOOD SAMPLING; CANNULA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DEGRADATION; DRUG DISTRIBUTION; HYDROPHILICITY; LIPOPHILICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BRAIN; CHOLERA TOXIN; DRUG CARRIERS; DRUG COMPOUNDING; MALE; METHOTREXATE; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 27844435108     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2005.09.006     Document Type: Article

References (59)

1. P. Artursson Epithelial transport of drugs in cell culture. I. A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells J. Pharm. Sci. 79 1990 476 482
2. P.F. Augustijins, and R.T. Borchardt Transport and matabolism of sleep inducing peptide in cultured human intestinal epithelial cell monolayers Drug Metab. Dispos. 23 1995 1372 1378
3. J.A. Bailer Testing for the equality of areas under the curves when using destructive measurement techniques J. Pharmacokinet. Biopharm. 16 1988 303 309
4. J. Bart, H.J. Groen, N.H. Hendrikse, W.T. van der Graaf, W. Vaalburg, and E.G. de Vries The blood-brain barrier and oncology: new insights into function and modulation Cancer Treat. Rev. 26 2000 449 462
5. A. Behin, K. Hoang-Xuan, A.F. Carpentier, and J.Y. Delattre Primary brain tumours in adults Lancet 361 2003 323 331
6. J.H. Beijnen, M.T. Huizing, W.W. ten Bokkel Huinink, C.H. Veenhof, J.B. Vermorken, G. Giaccone, and H.M. Pinedo Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol) Semin. Oncol. 21 1994 53 62
7. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J. Natl. Cancer Inst. 92 2000 1295 1302
8. M.W. Bradbury The structure and function of the blood-brain barrier Fed. Proc. 43 1984 186 190
9. P. Breedveld, N. Zelcer, D. Pluim, O. Sonmezer, M.M. Tibben, J.H. Beijnen, A.H. Schinkel, O. van Tellingen, P. Borst, and J.H. Schellens Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions Cancer Res. 64 2004 5804 5811
10. D.A. Cairnes, and W.E. Evans High performance liquid chromatographic assay of methotrexate, 7-hydroxymethotrxate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid J. Chromatogr.: Biomed. Appl. 231 1982 103 110
11. B.W. Corn, S.M. Marcus, A. Topham, W. Hauck, and W.J. Curran Jr. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 79 1997 2409 2413
12. W. Cosolo, and N. Christophidis Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats Cancer Res. 47 1987 6225 6228
13. T.R. Cote Epidemiology of brain lymphoma among people with or wihtout accquired immunodeficiency syndrome J. Natl. Cancer Inst. 88 1996 675 679
14. D.S. Cox, H. Gao, S. Raje, K.R. Scott, and N.D. Eddington Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin Eur. J. Pharm. Biopharm. 52 2001 145 150
15. D.S. Cox, S. Raje, H. Gao, N.N. Salami, and N.D. Eddington Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin Pharm. Res. 19 2002 1680 1688
16. T. Cresteil, B. Monsarrat, P. Alvinerie, J.M. Treluyer, I. Vieira, and M. Wright Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation Cancer Res. 54 1994 386 392
17. M. Di Pierro, R. Lu, S. Uzzau, W. Wang, K. Margaretten, C. Pazzani, F. Maimone, and A. Fasano Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain J. Biol. Chem. 276 2001 19160 19165
18. A. Fasano, B. Baudry, D.W. Pumplin, S.S. Wasserman, B.D. Tall, J.M. Ketley, and J.B. Kaper Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions Proc. Natl. Acad. Sci. U.S.A. 88 1991 5242 5246
19. A. Fasano, C. Fiorentini, G. Donelli, S. Uzzau, J.B. Kaper, K. Margaretten, X. Ding, S. Guandalini, L. Comstock, and S.E. Goldblum Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro J. Clin. Invest. 96 1995 710 720
20. A. Fasano, and S. Uzzau J. Clin. Invest. 99 1997 1158 1164
21. A. Fasano, and S. Uzzau Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model J. Clin. Invest. 99 1997 1158 1164
22. A. Fasano, S. Uzzau, C. Fiore, and K. Margaretten The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway Gastroenterology 112 1997 839 846
23. S. Fellner, B. Bauer, D.S. Miller, M. Schaffrik, M. Fankhanel, T. Spruss, G. Bernhardt, C. Graeff, L. Farber, H. Gschaidmeier, A. Buschauer, and G. Fricker Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo J. Clin. Invest. 110 2002 1309 1318
24. H. Fischer, R. Gottschlich, and A. Seelig Blood-brain barrier permeation: molecular parameters governing passive diffusion J. Membr. Biol. 165 1998 201 211
25. P.L. Golden, and G.M. Pollack Blood-brain barrier efflux transport J. Pharm. Sci. 92 2003 1739 1753
26. J.W. Harris, A. Rahman, B.R. Kim, F.P. Guengerich, and J.M. Collins Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme Cancer Res. 54 1994 4026 4035
27. F.M. Huennekens The methotrexate story: a paradigm for development of cancer chemotherapeutic agents Adv. Enzyme Regul. 34 1994 397 419
28. T. Inamura, T. Nomura, R.T. Bartus, and K.L. Black Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors J. Neurosurg. 81 1994 752 758
29. C.S. Karyekar, and N.D. Eddington Proceedings of the 17th National Meeting on Annual American Association of Pharmaceutical Scientists Toronto, Canada 2002
30. C.S. Karyekar, and N.D. Eddington Proceedings of the 17th National Meeting on Annual American Association of Pharmaceutical Scientists Toronto, Canada 2002
31. C.S. Karyekar, A. Fasano, S. Raje, R. Lu, T.C. Dowling, and N.D. Eddington Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells J. Pharm. Sci. 92 2003 414 423
32. E.M. Kemper, A.E. van Zandbergen, C. Cleypool, H.A. Mos, W. Boogerd, J.H. Beijnen, and O. van Tellingen Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein Clin. Cancer Res. 9 2003 2849 2855
33. R.A. Kroll, and E.A. Neuwelt Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means Neurosurgery 42 1998 1083 1099 (discussion 1099-1100)
34. R.A. Kroll, M.A. Pagel, L.L. Muldoon, S. Roman-Goldstein, S.A. Fiamengo, and E.A. Neuwelt Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers Neurosurgery 43 1998 879 886 (discussion 886-889)
35. J.M. Legler, L.A. Ries, M.A. Smith, J.L. Warren, E.F. Heineman, R.S. Kaplan, and M.S. Linet Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality J. Natl. Cancer Inst. 91 1999 1382 1390
36. 3H]-paclitaxel in rats: a quantitative autoradiographic study Cancer Chemother. Pharmacol. 37 1995 173 178
37. V.A. Levin Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability J. Med. Chem. 23 1980 682 684
38. Louis, D.N., Posner, J., Jacobs, T., Kaplan, R., 2000. Report of the Brain Tumor Progress Review Group. National Cancer Institute, National Institute of Neurological Disorders and Stroke, pp. 19-20.
39. R. Lu, W. Wang, S. Uzzau, R. Vigorito, H.R. Zielke, and A. Fasano Affinity purification and partial characterization of the zonulin/zonula occludens toxin (Zot) receptor from human brain J. Neurochem. 74 2000 320 326
40. K.L. Lutz, and T.J. Siahaan Molecular structure of the apical junction complex and its contribution to the paracellular barrier J. Pharm. Sci. 86 1997 977 984
41. E.A. Neuwelt Therapeutic potential for blood-brain barrier modification in malignant brain tumor Prog. Exp. Tumor Res. 28 1984 51 66
42. E.A. Neuwelt, D.L. Goldman, S.A. Dahlborg, J. Crossen, F. Ramsey, S. Roman-Goldstein, R. Braziel, and B. Dana Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function J. Clin. Oncol. 9 1991 1580 1590
43. W.M. Pardridge Drug delivery to the brain J. Cereb. Blood Flow Metab. 17 1997 713 731
44. W.M. Pardridge Brain drug targeting and gene technologies Jpn. J. Pharmacol. 87 2001 97 103
45. W.M. Pardridge Blood-brain barrier drug targeting: the future of brain drug development Mol. Interv. 3 2003 pp. 90-105, 51
46. W.M. Pardridge, D. Triguero, J. Yang, and P.A. Cancilla Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier J. Pharmacol. Exp. Ther. 253 1990 884 891
47. M.D. Prados, S.J.S. Schold, H.A. Fine, K. Jaeckle, F. Hochberg, L. Mechtler, M.R. Fetell, S. Phuphanich, L. Feun, T.J. Janus, K. Ford, and W. Graney A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma Neuro-oncol 5 2003 96 103
48. A. Reggev, and I. Djerassi The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients Cancer 61 1988 2423 2428
49. A. Rice, M.L. Michaelis, G. Georg, Y. Liu, B. Turunen, and K.L. Audus Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors J. Mol. Neurosci. 20 2003 339 343
50. L.L. Rubin, and J.M. Staddon The cell biology of the blood-brain barrier Annu. Rev. Neurosci. 22 1999 11 28
51. N.N. Salama, A. Fasano, R. Lu, and N.D. Eddington Effect of the biologically active fragment of zonula occludens toxin, ΔG, on the intestinal paracellular transport and oral absorption of mannitol Int. J. Pharm. 251 2003 113 121
52. N.N. Salama, A. Fasano, M. Thakar, and N.D. Eddington The effect of ΔG on the transport and oral absorption of macromolecules J. Pharm. Sci. 93 2004 1310 1319
53. N.N. Salama, A. Fasano, M. Thakar, and N.D. Eddington The impact of ΔG on the oral bioavailability of low bioavailable therapeutic agents J. Pharmacol. Exp. Ther. 312 2005 199 205
54. E. Scheufler, G. Zetler, and H. Iven Pharmacokinetics and organ distribution of methotrexate in the rat Pharmacology 23 1981 75 81
55. T. Siegal, R. Rubinstein, F. Bokstein, A. Schwartz, A. Lossos, E. Shalom, R. Chisin, and J.M. Gomori In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans J. Neurosurg. 92 2000 599 605
56. T. Siegal, and E. Zylber-Katz Strategies for increasing drug delivery to the brain: focus on brain lymphoma Clin. Pharmacokinet. 41 2002 171 186
57. C. Unger, H. Eibl, H.W. von Heyden, B. Krisch, and G.A. Nagel Blood-brain barrier and the penetration of cytostatic drugs Klin. Wochenschr. 63 1985 565 571
58. J. van Asperen, O. van Tellingen, A. Sparreboom, A.H. Schinkel, P. Borst, W.J. Nooijen, and J.H. Beijnen Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833 Br. J. Cancer 76 1997 1181 1183
59. M. Yazdanian Blood-brain properties of human immunodeficiency virus antiretrovirals J. Pharm. Sci. 88 1999 950 954